<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03521583</url>
  </required_header>
  <id_info>
    <org_study_id>NL62238.078.18</org_study_id>
    <nct_id>NCT03521583</nct_id>
  </id_info>
  <brief_title>Von Willebrand Disease in the Netherlands</brief_title>
  <acronym>WiN-Pro</acronym>
  <official_title>Von Willebrand Disease in the Netherlands - Prospective Study (WiN-Pro)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stichting Haemophilia (Dutch Haemophilia Foundation)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to prospectively investigate the current bleeding tendency
      of children and adults with VWD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Von Willebrand disease (VWD) is the most common inherited bleeding disorder, and is
      characterized by a defective platelet adhesion and aggregation. VWD is caused by a reduced
      (type 1), an abnormal function (type 2) or a complete absence (type 3) of von Willebrand
      factor (VWF).

      In recent years, large retrospective cohort studies have provided valuable insights on the
      clinical presentation, bleeding phenotype, quality of life, diagnostics, genetics and
      treatment of patients with VWD. One of these large studies is the von Willebrand in the
      Netherlands (WiN) study, which is a nationwide cross sectional study of moderate and severe
      von Willebrand disease patients, that was initiated in 2007. Over 800 VWD patients were
      included in the WiN study, which was about 80% of all known VWD patients in the Netherlands.
      Although the WiN study and large retrospective studies in other countries provided important
      insights in understanding VWD, some significant challenges remain and large prospective
      studies are lacking to provide answers.

      All large retrospective cohort studies have assessed the bleeding phenotype of patients with
      VWD using bleeding scores or retrospective questionnaires. Bleeding scores calculate the sum
      of all bleeding episodes during lifetime. Therefore, they provide useful information on the
      bleeding tendency during lifetime. However, bleeding scores do not provide information on the
      change of bleeding tendency. If a patient had a period in his or her lifetime in which he or
      she had many bleeding episodes, then the bleeding score is high. Though, the patient could
      have had those bleeds 30 years ago and did not have a bleeding episode since then. Therefore,
      bleeding scores do not provide information on the current bleeding phenotype of VWD patients.
      Furthermore, previous studies provided limited information on the frequency of mild
      bleedings, like gum bleeding or epistaxis, that occur in daily life but do not require
      therapy. Nevertheless, these bleeding episodes can cause a major impairment in quality of
      life. This is especially important in children, because school-going children with VWD have a
      lower quality of life and have a different bleeding tendency, characterized by more cutaneous
      bleeding (81%), oropharyngeal bleeding (64%) and epistaxis (56%).

      Therefore, the primary aim of this study is to prospectively investigate the current bleeding
      tendency of children and adults with VWD.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2018</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding rate</measure>
    <time_frame>2 years</time_frame>
    <description>Number of bleedings in an individual divided by the follow-up duration</description>
  </primary_outcome>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Von Willebrand Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Von Willebrand disease patients known in a Hemophilia Treatment Center in the Netherlands
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Historically lowest VWF:Ag and/or VWF:RCo and/or VWF:CB ≤ 0.30 IU/mL and/or FVIII:C ≤
             0.40 IU/mL

          -  Treatment at a Hemophilia treatment center in the Netherlands

          -  All types of VWD

          -  All ages

        Exclusion Criteria:

        - Other known bleeding disorders present.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank WG Leebeek, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ferdows Atiq, MD</last_name>
    <role>Study Director</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marjon H Cnossen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karin Fijnvandraat, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeroen Eikenboom, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johanna G van der Bom, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Britta AP Laros-van Gorkom, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karina Meijer, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karin PM van Galen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joke de Meris</last_name>
    <role>Study Chair</role>
    <affiliation>Netherlands Hemophilia Society</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frank WG Leebeek, MD, PhD</last_name>
    <phone>+31107031369</phone>
    <email>f.leebeek@erasmusmc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Haga Hospital</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maxima Medical Center</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center +</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Leebeek FW, Eikenboom JC. Von Willebrand's Disease. N Engl J Med. 2016 Nov 24;375(21):2067-2080. Review.</citation>
    <PMID>27959741</PMID>
  </reference>
  <reference>
    <citation>Sanders YV, Groeneveld D, Meijer K, Fijnvandraat K, Cnossen MH, van der Bom JG, Coppens M, de Meris J, Laros-van Gorkom BA, Mauser-Bunschoten EP, Leebeek FW, Eikenboom J; WiN study group. von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. Blood. 2015 May 7;125(19):3006-13. doi: 10.1182/blood-2014-09-603241. Epub 2015 Feb 11.</citation>
    <PMID>25673639</PMID>
  </reference>
  <reference>
    <citation>de Wee EM, Mauser-Bunschoten EP, Van Der Bom JG, Degenaar-Dujardin ME, Eikenboom HC, Fijnvandraat K, de Goede-Bolder A, Laros-van Gorkom BA, Meijer K, Raat H, Leebeek FW; Win Study Group. Health-related quality of life among adult patients with moderate and severe von Willebrand disease. J Thromb Haemost. 2010 Jul;8(7):1492-9. doi: 10.1111/j.1538-7836.2010.03864.x. Epub 2010 Mar 23.</citation>
    <PMID>20345712</PMID>
  </reference>
  <reference>
    <citation>de Wee EM, Sanders YV, Mauser-Bunschoten EP, van der Bom JG, Degenaar-Dujardin ME, Eikenboom J, de Goede-Bolder A, Laros-van Gorkom BA, Meijer K, Hamulyák K, Nijziel MR, Fijnvandraat K, Leebeek FW; WiN study group. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost. 2012 Oct;108(4):683-92. Epub 2012 Aug 23.</citation>
    <PMID>22918553</PMID>
  </reference>
  <reference>
    <citation>van Galen KPM, de Kleijn P, Foppen W, Eikenboom J, Meijer K, Schutgens REG, Fischer K, Cnossen MH, de Meris J, Fijnvandraat K, van der Bom JG, Laros-van Gorkom BAP, Leebeek FWG, Mauser-Bunschoten EP; Win study group. Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study. Haematologica. 2017 Sep;102(9):1486-1493. doi: 10.3324/haematol.2017.168617. Epub 2017 Jun 1.</citation>
    <PMID>28572165</PMID>
  </reference>
  <reference>
    <citation>Sanders YV, Fijnvandraat K, Boender J, Mauser-Bunschoten EP, van der Bom JG, de Meris J, Smiers FJ, Granzen B, Brons P, Tamminga RY, Cnossen MH, Leebeek FW; WiN Study Group. Bleeding spectrum in children with moderate or severe von Willebrand disease: Relevance of pediatric-specific bleeding. Am J Hematol. 2015 Dec;90(12):1142-8. doi: 10.1002/ajh.24195. Epub 2015 Nov 17.</citation>
    <PMID>26375306</PMID>
  </reference>
  <reference>
    <citation>van Galen KP, Meijer K, Vogely HC, Eikenboom J, Schutgens RE, Cnossen MH, Fijnvandraat K, van der Bom JG, Laros-van Gorkom BA, Leebeek FW, Mauser-Bunschoten EP; WiN study group. Joint surgery in von Willebrand disease: a multicentre cross-sectional study. Haemophilia. 2015 Nov 9. doi: 10.1111/hae.12834. [Epub ahead of print]</citation>
    <PMID>26551280</PMID>
  </reference>
  <reference>
    <citation>Atiq F, Meijer K, Eikenboom J, Fijnvandraat K, Mauser-Bunschoten EP, van Galen KPM, Nijziel MR, Ypma PF, de Meris J, Laros-van Gorkom BAP, van der Bom JG, de Maat MP, Cnossen MH, Leebeek FWG; WiN study group. Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease. Br J Haematol. 2018 May 16. doi: 10.1111/bjh.15277. [Epub ahead of print]</citation>
    <PMID>29767844</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2018</study_first_submitted>
  <study_first_submitted_qc>April 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2018</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Frank W.G. Leebeek, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>von Willebrand disease</keyword>
  <keyword>von Willebrand factor</keyword>
  <keyword>Nationwide study</keyword>
  <keyword>Prospective study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

